Localization of medullary thyroid carcinoma after surgery using 11C-methionine pet/ct: Comparison with 18F-FDG PET/CT

Endocrine Journal

Volumn 57, Issue 12, 2010, Pages 1045-1054

  Jang, Hye Won ^a   Choi, Joon Young ^a   Lee, Ji In ^a   Kim, Hee Kyung ^a   Shin, Hyun Won ^a   Shin, Jung Hee ^a   Kim, Sun Wook ^a   Chung, Jae Hoon ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

11C methionine; 18F fuorodeoxyglucose; Medullary thyroid carcinoma; PET

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE F 18; METHIONINE C 11; PENTETREOTIDE IN 111;

ARTICLE; ASPIRATION BIOPSY; BONE SCINTISCANNING; CALCITONIN BLOOD LEVEL; CERVICAL LYMPH NODE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ECHOGRAPHY; FEMALE; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; MALE; MINIMAL RESIDUAL DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; TUMOR LOCALIZATION;

ADULT; AGED; CALCITONIN; CARBON RADIOISOTOPES; CARCINOMA, MEDULLARY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; METHIONINE; MIDDLE AGED; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 78650564928     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K10E-258     Document Type: Article

References (31)

1. Kebebew E, Ituarte PH, Siperstein AE, Duh Q Y, Clark OH (2000) Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 88: 1139-1148.
2. Stepanas AV, Samaan NA, Hill CS, Jr., Hickey RC (1979) Medullary thyroid carcinoma: importance of serial serum calcitonin measurement. Cancer 43: 825-837.
3. Fugazzola L, Pinchera A, Luchetti F, Iacconi P, Miccoli P, Romei C, Puccini M, Pacini F (1994) Disappearance rate of serum calcitonin after total thyroidectomy for medullary thyroid carcinoma. Int J Biol Markers 9: 21-24.
4. Clarke SE, Lazarus CR, Wraight P, Sampson C, Maisey MN (1988) Pentavalent [99mTc]DMSA, [131I]MIBG, and [99mTc]MDP--an evaluation of three imaging techniques in patients with medullary carcinoma of the thyroid. J Nucl Med 29: 33-38.
5. Berna L, Cabezas R, Mora J, Torres G, Estorch M, Carrio I (1995) 111In-octreotide and 99mTc(V)-dimercaptosuccinic acid studies in the imaging of recurrent medullary thyroid carcinoma. J Endocrinol 144: 339-345.
6. Krausz Y, Rosler A, Guttmann H, Ish-Shalom S, Shibley N, Chisin R, Glaser B (1999) Somatostatin receptor scintigraphy for early detection of regional and distant metastases of medullary carcinoma of the thyroid. Clin Nucl Med 24: 256-260.
7. Adams S, Baum RP, Hertel A, Schumm-Draeger PM, Usadel KH, Hor G (1998) Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological fndings. Eur J Nucl Med 25: 1277-1283.
8. de Groot JW, Links TP, Jager PL, Kahraman T, Plukker JT (2004) Impact of 18F-fuoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol 11: 786-794.
9. Szakall S, Jr., Esik O, Bajzik G, Repa I, Dabasi G, Sinkovics I, Agoston P, Tron L (2002) 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med 43: 66-71.
10. Diehl M, Risse JH, Brandt-Mainz K, Dietlein M, Bohuslavizki KH, Matheja P, Lange H, Bredow J, Korber C, Grunwald F (2001) Fluorine-18 fuorodeox-yglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. Eur J Nucl Med 28: 1671-1676.
11. Rubello D, Rampin L, Nanni C, Banti E, Ferdeghini M, Fanti S, Al-Nahhas A, Gross MD (2008) The role of 18F-FDG PET/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: a prospective study. Eur J Surg Oncol 34: 581-586.
12. Kubota K, Matsuzawa T, Fujiwara T, Sato T, Tada M, Ido T, Ishiwata K (1989) Differential diagnosis of AH109A tumor and inflammation by radio scintigraphy with L-[methyl-11C]methionine. Jpn J Cancer Res 80: 778-782.
13. Hoffman RM (1984) Altered methionine metabolism, DNA methylation and oncogene expression in carcino-genesis. A review and synthesis. Biochim Biophys Acta 738: 49-87.
14. Jana S, Blaufox MD (2006) Nuclear medicine studies of the prostate, testes, and bladder. Seminars in Nuclear Medicine 36: 51-72.
15. Leskinen-Kallio S, Lindholm P, Lapela M, Joensuu H, Nordman E (1994) Imaging of head and neck tumors with positron emission tomography and [11C]methion-ine. Int J Radiat Oncol Biol Phys 30: 1195-1199.
16. Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ, Piers DA (2001) Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 42: 432-445.
17. Leskinen-Kallio S, Nagren K, Lehikoinen P, Ruotsalainen U, Teras M, Joensuu H (1992) Carbon-11-methionine and PET is an effective method to image head and neck cancer. J Nucl Med 33: 691-695.
18. Hsieh HJ, Lin SH, Lin KH, Lee CY, Chang CP, Wang SJ (2008) The feasibility of 11C-methionine-PET in diagnosis of solitary lung nodules/masses when compared with 18F-FDG-PET. Ann Nucl Med 22: 533-538.
19. Wieder H, Ott K, Zimmermann F, Nekarda H, Stollfuss J, Watzlowik P, Siewert JR, Fink U, Becker K, Schwaiger M, Weber WA (2002) PET imaging with [11C]methyl-L-methionine for therapy monitoring in patients with rectal cancer. European Journal of Nuclear Medicine and Molecular Imaging 29: 789-796.
20. Nunez R, Macapinlac HA, Yeung HW, Akhurst T, Cai S, Osman I, Gonen M, Riedel E, Scher HI, Larson SM (2002) Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med 43: 46-55.
21. Lindholm P, Lapela M, Nagren K, Lehikoinen P, Minn H, Jyrkkio S (2009) Preliminary study of carbon-11 methionine PET in the evaluation of early response to therapy in advanced breast cancer. Nucl Med Commun 30: 30-36.
22. Phan HT, Jager PL, Plukker JT, Wolffenbuttel BH, Dierckx RA, Links TP (2008) Comparison of 11C-me-thionine PET and 18F-fuorodeoxyglucose PET in differentiated thyroid cancer. Nucl Med Commun 29: 711-716.
23. HW Jang, JI Lee, KY Hur, JH Kim, SW Kim, YK Min, MS Lee, MK Lee, KW Kim, JH Chung (2010) Clinicopathological characteristics and prognostic factors of medullary thyroid carcinoma. Endocrinol Metab 25: 183-191.
24. Koopmans KP, de Vries EG, Kema IP, Elsinga PH, Neels OC, Sluiter WJ, van der Horst-Schrivers AN, Jager PL (2006) Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncology 7: 728-734.
25. Koopmans KP, de Groot JW, Plukker JT, de Vries EG, Kema IP, Sluiter WJ, Jager PL, Links TP (2008) 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. J Nucl Med 49: 524-531.
26. Laure Giraudet A, Al Ghulzan A, Auperin A, Leboulleux S, Chehboun A, Troalen F, Dromain C, Lumbroso J, Baudin E, Schlumberger M (2008) Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol 158: 239-246.
27. Giraudet AL, Vanel D, Leboulleux S, Auperin A, Dromain C, Chami L, Ny Tovo N, Lumbroso J, Lassau N, Bonniaud G, Hartl D, Travagli JP, Baudin E, Schlumberger M (2007) Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab 92: 4185-4190.
28. Ong SC, Schoder H, Patel SG, Tabangay-Lim IM, Doddamane I, Gonen M, Shaha AR, Tuttle RM, Shah JP, Larson SM (2007) Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med 48:501-507.
29. Grunwald F, Schomburg A, Bender H, Klemm E, Menzel C, Bultmann T, Palmedo H, Ruhlmann J, Kozak B, Biersack HJ (1996) Fluorine-18 fuorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 23: 312-319.
30. Adams S, Baum RP, Hertel A, Schumm-Drager PM, Usadel KH, Hor G (1998) Metabolic (PET) and receptor (SPET) imaging of well- and less well-differentiated tumours: comparison with the expression of the Ki-67 antigen. Nucl Med Commun 19: 641-647.
31. Busnardo B, Girelli ME, Simioni N, Nacamulli D, Busetto E (1984) Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma. Cancer 53: 278-285.